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of chondrogenic potency and trophic properties of MSCs. The meas-
urement of MMP13 gene and TIMP-1 protein markers will facilitate the
design of future therapeutic strategies that exploit either of one these
modes of action.757
AN IN VITRO STUDY TO INVESTIGATE THE EFFECTS OF STEM CELL
THERAPY FOR TREATING OSTEOARTHRITIS
J. Li, C. Little. Kolling Inst., Univ. of Sydney, Sydney, Australia
Purpose: Osteoarthritis (OA) is a leading cause of chronic pain and
disability, for which there is no cure. A range of non-operative treat-
ments are used clinically, but only to manage symptoms until joint
degeneration becomes so severe that an operation is performed to
remove the diseased joint. Mesenchymal stem cells (MSCs) have
recently brought new hope for treating OA due to their unique secretory
functions, which send anti-inflammatory and trophic signals to thesurrounding tissues. Interestingly, although the few available Phase I
and II clinical trials utilising MSCs to treat knee OA have shown short-
term effects in improving pain and joint function, they have not dem-
onstrated sustained benefits. This may reflect a depletion of injected
MSCs from the joint or a change/loss in their anti-inflammatory phe-
notype, and raises the question of whether repeated treatment by MSC
injection will be beneficial.
Methods: We co-cultured bone marrow-derived human MSCs with
human synovial fibroblasts (HSFs) isolated from osteoarthritic joint
tissues. (1) To test whether osteoarthritic cells canmodify the behaviour
of MSCs, HSFs were co-cultured with human MSCs in growth, osteo-
genic and chondrogenic media, which simulated the types of conditions
relevant for an osteoarthritic joint. (2) To test whether exposing
osteoarthritic cells to MSCs can cause sustained changes in their
behaviour and have positive effects on tissue repair, HSFs were either
pre-conditioned by first co-culturing with MSCs for 3 days (þcHSF), or
not pre-conditioned and simply cultured in growth medium (þHSF),
and subsequently co-cultured with fresh MSCs in growth, osteogenic
and chondrogenic media for 3 and 7 days. In both experiments, quan-
titative RT-PCR (n¼4; mean ± SD) was used to evaluate inflammatory
response in the MSCs and HSFs (IL-6, IL-8, MMP-2, MMP-13, ADAMTS4,
ADAMTS5, CD44, TLR4, COX-2, CCL2), as well as differentiation in the
MSCs (RUNX2, BSP, SPP1 for osteogenesis; SOX9, COL2A1, ACAN for
chondrogenesis). In the first experiment, histology (n¼2) was per-
formed at 21 days to compare osteogenesis and chondrogenesis inMSCs
between groups. Data was analysed using t-tests with P<0.05 consid-
ered statistically significant.
Results: MSCs co-cultured with osteoarthritic HSFs (Figure 1A) showed
significant upregulation of several markers of inflammation, matrix
degradation and tissue degeneration (e.g. MMP2, ADAMTS5, IL-8,
CD44). They also showed significantly impaired ability to form new
bone and cartilage, as evidenced by reduced expression of markers for
osteogenesis (BSP, SPP1) and chondrogenesis (COL2A1, ACAN), and
reduced histological features of differentiated bone (calcium) and car-
tilage (proteoglycan). These findings suggest that the osteoarthritic
joint is a highly inhibitory environment that can increase inflammation
in MSCs and significantly impair their regenerative ability. This explains
clinical findings where MSCs did not have sustained therapeutic effects
for knee OA.
Pre-conditioning the HSFs by exposing them to MSCs did not have any
significant positive effects in modifying their behaviour (Figure 1B).
HSFs, pre-conditioned or not, caused similar levels of inflammatory
marker expression in MSCs in different media types and at different
time points (e.g. ADAMTS4, IL-8, CD44). MSCs co-cultured with both
pre-conditioned and non-pre-conditioned HSFs also showed impaired
chondrogenesis to a similar extent (e.g. SOX9 expression, histology).
Comparing the pre-conditioned and non-preconditioned HSFs, similar
gene expression profiles were observed and pre-conditioning did not
induce significant changes in the inflammatory phenotype of HSFs.
These findings suggest that short-term exposure of osteoarthritic cells
to MSCs is insufficient for sustained modifications to their diseased
phenotype. Therefore, repeated MSC injections are unlikely to improve
therapeutic efficacy in OA.
Conclusions: Although MSCs have anti-inflammatory and trophic
functions, they could not provide long-term effects in correcting the
osteoarthritic joint environment due to adopting the diseased pheno-
type of the surrounding tissues. Future regenerative therapies for OA
that investigate the use of stem cells should shift focus away from
testing different cell sources, injection concentrations and admin-
istration frequencies, and work on correcting the catabolic environment
within the osteoarthritic joint, or utilise the biological derivatives of
Abstracts / Osteoarthritis and Cartilage 28 (2020) S86eS527S504stem cells which, unlike the living cell, will not respond in a negative
way to the osteoarthritic environment.
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HYALURONIC ACID-BASED SHAPE MEMORY CRYOGEL SCAFFOLDS
FOR FOCAL CARTILAGE DEFECT REPAIR
T. He 1, B. Li 1, T. Colombani 2, K.J. Navare 2, S.A. Bencherif 2,3,
A.G. Bajpayee 1. 1Dept. of Bioengineering, Northeastern Univ., Boston, MA;
2Dept. of Chemical Engineering, Northeastern Univ., Boston, MA; 3 John A.
Paulson Sch. of Engineering and Applied Sci., Harvard Univ., Cambridge,
MA
Purpose: Traumatic joint injuries can result in focal cartilage defects
that regenerate poorly due to a lack of blood supply and low chon-
drocyte density. Cell-laden hydrogel scaffolds are under study but
provide little flexibility in modulating their pore size, interconnectivity,
swelling and stiffness, properties required for a conducive biomimetic
environment. In this study, we engineered an injectable and biomimetic
shape memory hyaluronic acid (HA)-based cryogel scaffolds with a
macroporous and highly interconnected network in three-dimensions
seeded with chondrocytes. Due to their unique ability to withstand up
to 90% strains and rapidly recover their shape back, they can be
arthroscopically delivered to fill up focal chondral defects for cartilage
repair. Here we studied whether chondrocytes encapsulated within
cryogels remain viable and metabolically active following injection and
provide a superior micro-environment than conventional (nanoporous)
hydrogels for cartilage regeneration. We also investigated how RGD-
functionalized cryogel affects chondrocyte adhesion, migration and
proliferation.
Methods: Synthesis of HA-based Cryogels and Hydrogels: HA cryogels
were prepared using HA modified with glycidyl methacrylate (HAGM)
and either Acryl-PEG-G4RGDS to synthesis gels functionalized with
RGD (Cryo RGDþ) or Acryl-PEG-methoxy to synthesize gels without
RGD (Cryo RGD-) in deionized (DI) water. The mixture was cast in 6 mm
diam x 1.5 mm cylindrical discs using APS/TEMED as our initiator sys-
tem. The samples were frozen at -20C and allowed to cryopolymerize
overnight. Next, cryogels were brought to RT and washed/sanitized
prior to cell seeding. HA hydrogels (Hydro RGDþ) were fabricated via
photopolymerization by mixing HAGM, RGD, and lithium phenyl-2,4,6-
trimethylbenzoylphosphinate (LAP) photo-initiator in DI water. Chon-
drocyte seeding and in-vitro culture:Chondrocytes harvested from calf
knee femoral condyle cartilage were seeded onto each scaffold and
cultured for 15 days. Injectability test: Cell-laden cryogels were incu-
bated overnight to enable complete cell adhesion and subsequently
syringe injected through a 16-gauge needle before incubation for
another 24h following which cell viability and metabolism were
quantified. Biochemical analysis: At the end of 15-day culture, gel sam-
ples were digested to quantify the cell metabolism (Alamar Blue), DNA
(PicoGreen) and GAG (DMMB) content. Cell viability and cytoskeleton
staining: Gel samples were fixed and stained for nucleus, actin, dead
cells and confocal imaged at 40x.
Results: Shape memory HA-based cryogels fully recovered their shape
back following syringe injection through a 16-gauge needle without
impacting cell metabolism or viability (Figs 1A-C). Scanning electron
microscopy (SEM) images showed an average pore size of 49.2 ± 15 mm
(Fig 1D) rendering amacroporous structurewith high interconnectivity,
which was 7x higher than hydrogels (Fig 1E). This unique macro-
structural architecture enables efficient transport of nutrients and
metabolites thereby offering a superior microenvironment for chon-
drocytes; both cell metabolism and GAG content was 2x higher in
cryogels than hydrogels after 15-day culture (Figs 1F-G). Additionally, asignificant amount of GAG (~70 mg) was released from both cryogels
into media owing to their macroporous structure; no released GAG was
measured in media from Hydro RGDþ (Fig 1G). The presence of RGD
(cell-adhesion peptide) did not improve cell adhesion or biosynthesis
rates. Chondrocytes formed larger organoid-like structures in Cryo
RGD- while remaining homogenously dispersed in the presence of RGD
in Cryo RGDþ (Fig 1H).
Conclusions: Syringe injectable HA-based shape memory cryogels
provide a conducive microenvironment for chondrocyte adhesion,
proliferation and matrix biosynthesis for use in repair of cartilage
defects.
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MICRORNA PROFILE OF MESENCHYMAL STROMAL CELLS: A TOOL TO
PREDICT THEIR THERAPEUTIC EFFICACY IN OSTEOARTHRITIS
R. Rabani 1, J. Chahal 1, N. Mahomed 1, K. Marshall 1, R. Gandhi 1,
S. Viswanathan 1,2. 1Arthritis Program, Krembil research Inst., Univ.
Hlth.Network, Toronto, ON, Canada; 2 Inst. of Biomaterials and BioMed.
Engineering, Univ. of Toronto. Div. of hematology, Dept. of Med., Univ. of
Toronto, Toronto, ON, Canada
Purpose: Osteoarthritis (OA) is a joint disease affecting > 5 million
Canadians. Patients have limited palliative and joint-replacement sur-
gical options, emphasizing the need for new curative therapies. Stromal
cell therapy is emerging as a compelling treatment for OA. Our first-in-
Canada Ph1/2 trial with bone marrow mesenchymal stromal cells (BM-
MSCs) in OA patients showed significant improvements in patient
outcomes. Pro-inflammatory monocytes/macrophages were reduced in
the synovial fluid (SF), suggestive of a clinical MSC anti-inflammatory
action. Although, MSCs showed beneficial effects in all the patients, we
found variabilities in MSCs efficacy among participants. The goal of this
study is to identify novel microRNAs (miRs) that correlate with ther-
apeutic efficacy of MSCs in the context of OA.
Methods: We have identified a panel of predictive anti-inflammatory
markers (i.e. IL10, HGF, IL6, TSG6, PGE2) on MSCs that is strongly indi-
cative of clinical efficacy in OA. To expend this panel, we have conducted
an unbiased miR sequencing on our clinical trial MSC samples exposed
to pooled synovial fluid from eight OA patients in the same trial. We are
correlating differential miR expression with patient outcomes.
Results: We have identified 25 miRs differentially expressed between
MSCs from responder (5/ out of 5 KOOS sub-scale responses are clin-
ically significant) and mild responder (2-3/5 KOOS sub-scale responses
are clinically significant) participants. Amongst these, 12 miRs showed
higher expression in MSCs from responder participants and 13 miRs
appeared to be expressed at lower level when compared to those levels
in MSCs from mild responder participants. Interestingly, we found that
the identified miRs are associated with immune response, fibrosis, OA
pathology and three linage differentiation of MSCs. Currently, we are
verifying the miRs and their targets by qPCR to better understand and
predict potent MSCs, and/or OA patients that are responders to MSC
therapies.
Conclusions: microRNA profile of MSCs contributes to therapeutic
efficacy of MSCs. Understanding therapeutically relevant mechanism of
action of MSCs will help to develop enhancedMSCs; and define potency
criterion for screening effective MSCs in OA patients. This in turn will
enable a successful MSC pivotal clinical trial in OA.
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KRÜPPEL-LIKE FACTOR 10 IS A IMPORTANT MODULATORY FACTOR
OF CHONDROCYTE HYPERTROPHY IN DEVELOPING SKELETON
J.-Y. Ko 1, E. Lee 1, J.-W. Park 1, J. Kim 1, G.-I. Im 2,1. 1Res. Inst. for Integrative
Regenerative BioMed. Engineering, Dongguk Univ., Goyang, Republic of
Korea; 2Dongguk Univ. Ilsan Hosp., Goyang, Republic of Korea
Purpose: To investigate the functional role of KLF10 as a modulator of
chondrocyte hypertrophy in developmental skeleton. The devel-
opmental characteristics in the long bone of KLF10 knockout mice and
characteristics of MSCs from KLF10 KO mice were investigated regard-
ing chondrogenesis and osteogenesis. Delayed long bone growth and
delayed formation of primary ossification center were observed in an
early embryonic stage in KLF10 KO mouse along with very low Ihh
expression in epiphyseal plate. While the chondrogenic potential of
mMSCs appeared normal or slight decrerased in KLF10 KO mice,
osteogenesis and hypertrophy were extensively suppressed. KLF10 was
